Heyholder
‹ Activism Filings

KANGSTEM BIOTECH CO., LTD. Q3 operating loss of KRW 5.3 billion on KRW 0.6 billion in sales

KANGSTEM BIOTECH CO., LTD.· Periodic Report

Operating profit · 3 months

KRW -5.3 billion

Key facts

Revenue (3 months)
KRW 612.8 million
Net income (3 months)
KRW -5.2 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 485.1 million
Revenue (year to date)
KRW 2.1 billion
Operating profit (prior-year 3 months)
KRW -4.2 billion
Operating profit (year to date)
KRW -16.0 billion
Net income (prior-year 3 months)
KRW -4.5 billion
Net income (year to date)
KRW -16.0 billion

Commentary

AI commentary · Not investment advice

What happened

Kangstem Biotech reported its consolidated results for the 3rd quarter of 2026. Sales for the latest 3 months were KRW 612.8 million. That is up 26.3% from KRW 485.1 million a year earlier. It is down 4.5% from the previous quarter. Cumulative sales this year are KRW 2.06 billion.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 5.33 billion. A year earlier, the same period showed a loss of KRW 4.19 billion. The cumulative operating loss this year is KRW 15.96 billion.

What changes for shareholders

Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 5.18 billion. A year earlier, it was a loss of KRW 4.46 billion. The cumulative net loss this year is KRW 15.99 billion.

Comments

No comments yet

Comments from shareholders will appear here.